Antengene Corp Ltd is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. The Company is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company's products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The Company mainly conducts its business in Asia-Pacific.

Employees

129

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-07-13	HK$4.410	+3.28%	1,611,500
26-07-10	HK$4.270	+5.17%	2,147,283
26-07-09	HK$4.060	+3.84%	1,292,272
26-07-08	HK$3.910	-2.25%	1,725,555
26-07-07	HK$4.000	-6.76%	1,369,000

Delayed Quote Hong Kong S.E.

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

3.814CNY

Average target price

4.379CNY

Spread / Average Target

+14.81%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Hong Kong S.E. Other stock markets 04:08:41 2026-07-13 EDT			5-day change	1st Jan Change
4.410 ^HKD	+3.28%		+2.08%	+16.36%

01:10am	Antengene Receives $60 Million Milestone in UCB Licensing Deal	MT
07-10	Soochow Securities Starts Antengene at Buy With HK$10.60 Price Target	MT

Market Cap	2.59B 2.99B 382M 335M 310M 286M 540M 36.57B 551M 3.7B 1.45B 17.96B 1.43B 1.4B 62.02B	P/E 2026 *	7.78x	P/E 2027 *	-
Enterprise Value	2.59B 2.99B 382M 335M 310M 286M 540M 36.57B 551M 3.7B 1.45B 17.96B 1.43B 1.4B 62.02B	EV / Sales 2026 *	3.66x	EV / Sales 2027 *	6.92x
Free-Float	60.39%	Yield 2026 *	-	Yield 2027 *	-

01:10am	Antengene Receives $60 Million Milestone in UCB Licensing Deal	MT
07-10	Soochow Securities Starts Antengene at Buy With HK$10.60 Price Target	MT
07-09	Antengene Corporation Limited commences an Equity Buyback Plan for 67,924,413 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2026.	CI
06-24	Antengene Plans Up to HK$50 Million Share Buyback	MT
06-22	Antengene Corporation Limited And K2 Therapeutics Enter Exclusive License Agreement For ATG-106 And Option For Undisclosed Bispecific TCE	CI
06-21	Antengene Licenses ATG-106 to K2 Therapeutics in Potential $981 Million Deal	MT
06-10	Antengene Corporation Ltd. Announces Executive Changes, Effective June 10, 2026	CI
06-09	Antengene Secures China IND Approval for Autoimmune Disease Drug	MT
06-09	Antengene Corporation Limited Receives IND Approval for ATG-201 (CD19 × CD3 TCE) In Autoimmune Disease In China	CI
06-07	Antengene Presents First Preclinical Data on ATG-207 At EULAR 2026	CI
06-03	Antengene Corporation Limited Presents First Preclinical Data On ATG-207 (aCD3-TGF-ß Bifunctional Fusion Protein) At EULAR 2026	CI
05-27	Antengene Secures Chinese Regulatory Nod for Phase 3 Trial	MT
05-27	Antengene receives CDE endorsement for phase III clinch-3 study of ATG-22 in China	RE

12:01am	Antengene Announces Receipt of USD 60 Million Upfront Payment from UCB	PR
06-21	Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE	PR
06-09	Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China	PR
06-07	Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance	PR
06-03	Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026	PR

Antengene Corporation Limited Stock

Stocks

6996

KYG039571008

Biotechnology & Medical Research

Valuation: Antengene Corporation Limited

Chart: Antengene Corporation Limited

Latest news : Antengene Corporation Limited

Analysts' recommendations: Antengene Corporation Limited

Press Releases: Antengene Corporation Limited

Quotes and Performance

Course Extremes

Managers and Directors: Antengene Corporation Limited

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

1 day	+3.28%
1 week	+2.08%
Current month	+24.93%
1 month	+23.53%
3 months	-21.39%
6 months	+6.52%
Current year	+16.36%

1 week	3.84	4.45
1 month	3.22	4.66
Current year	2.76	6.28
1 year	2.76	8.16
3 years	0.5	8.16
5 years	0.5	18.48
10 years	0.5	22.5

Manager	Title	Age	Since
Jian Ming Mei CEO	Chief Executive Officer	60	2018-08-27
Donald Lung DFI	Director of Finance/CFO	44	2020-06-07
Bing Hou CTO	Chief Tech/Sci/R&D Officer	-	2026-05-19

Director	Title	Age	Since
Jian Ming Mei CHM	Chairman	60	2018-08-27
Jing Qian BRD	Director/Board Member	51	2020-11-08
Donald Lung BRD	Director/Board Member	44	2021-06-17

Date	Insider	Type	Main position	Quantity	% Market Cap.
04-01	Jian Ming Mei	Other	Chief Executive Officer	600,000	0.0883%
03-23	Donald Lung	Other	Chief Financial Officer	235,000	0.0346%
03-23	Jian Ming Mei	Other	Chief Executive Officer	100,000	0.0147%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ANTENGENE CORPORATION LIMITED	+3.28%	+2.08%	+45.07%	+197.97%	370M
WUXI APPTEC CO., LTD.	-2.48%	-3.13%	+55.85%	+89.65%	54.88B
ARGENX SE	-0.55%	-6.57%	+55.85%	+128.31%	54.63B
INSMED INCORPORATED	-5.52%	-2.51%	+6.72%	+418.53%	25.06B
BIONTECH SE	-1.91%	-4.36%	-19.07%	-17.97%	23.14B
WUXI BIOLOGICS (CAYMAN) INC.	-1.69%	-0.64%	+40.04%	-0.48%	19.87B
GENMAB A/S	+1.87%	+4.16%	+38.74%	-26.42%	17.55B
PHARMAESSENTIA CORPORATION	-2.72%	-0.60%	+187.08%	+351.91%	16.5B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-2.42%	+1.00%	+48.24%	+635.77%	15.75B
EXELIXIS, INC.	-0.80%	+0.58%	+22.53%	+188.63%	14.2B
Average	-1.29%	-0.85%	+48.10%	+196.59%	24.19B
Weighted average by Cap.	-1.83%	-1.56%	+47.54%	+165.74%

	2026 *	2027 *
Net sales	708M 819M 104M 91.63M 84.87M 78.09M 148M 10B 151M 1.01B 397M 4.91B 392M 384M 16.96B	374M 433M 55.2M 48.41M 44.84M 41.26M 78.04M 5.28B 79.56M 534M 210M 2.59B 207M 203M 8.96B
Net income	308M 356M 45.46M 39.87M 36.93M 33.98M 64.26M 4.35B 65.51M 440M 173M 2.14B 171M 167M 7.38B	-247K -286K -36.43K -31.95K -29.59K -27.23K -51.5K -3.49M -52.5K -353K -138K -1.71M -137K -134K -5.91M
Net Debt	-	-